Immunex regulatory update

IMNX filed an SBLA with the FDA for its Enbrel etanercept to treat moderate to severe polyarticular course juvenile rheumatoid arthritis (RA). Enbrel received FDA approval in November to treat RA in patients with inadequate responses to one or more disease modifying anti-rheumatic drugs or in combination with methotrexate in patients who do not respond to methotrexate alone (see BioCentury Extra, Nov. 3). ...